Johnson & Johnson's Q3 2013 earnings call revealed strong performance in the pharmaceutical segment, driven by new product launches such as ZYTIGA, XARELTO, and INVOKANA. The company's medical devices and diagnostics segment faced challenges, including pricing pressures and market share losses in certain areas. Despite these challenges, management expressed confidence in the company's ability to drive growth through innovation, emerging markets, and strategic partnerships. The stock is likely to react positively to the strong pharmaceutical segment performance and the company's efforts to address challenges in the medical devices segment.

[1]